Join the Lower Limb Spasticity group to help and get support from people like you.
Lower Limb Spasticity News
Experimental Drug Can Slow MS Disability
WEDNESDAY, April 9, 2025 – An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder, a new clinical trial...
AAN: Tolebrutinib Slows Disability in Nonrelapsing Secondary Progressive MS
WEDNESDAY, April 9, 2025 – Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation within the central nervous system, slows...
MS Patients May Benefit From Eating More Fish
WEDNESDAY, Feb. 26, 2025 – A diet rich in fish might slow the progression of multiple sclerosis in some patients, a new study says. The nutrients found in fish can quell inflammation and protect...
Pregnancy Increases Mental Health Risk in MS Patients
THURSDAY, Jan. 23, 2025 – Pregnancy increases the risk of mental illness among women with multiple sclerosis (MS). Pregnant MS patients have a higher risk of mental illness both during gestation and...
Children Have Various Symptoms Within Five Years Before MS Diagnosis
FRIDAY, Dec. 27, 2024 – Children and adolescents with multiple sclerosis (MS) have a range of symptoms, signs, and diagnoses within five years before diagnosis, according to a study published online...
Social Determinants of Health Linked to Brain MRI Outcomes in Pediatric MS
MONDAY, Dec. 2, 2024 – For patients with pediatric-onset multiple sclerosis (POMS), social determinants of health (SDOH) are associated with worse brain magnetic resonance imaging (MRI) outcomes,...
What Works Best to Ease MS-Linked Fatigue? New Study Finds Out
FRIDAY, Oct. 25, 2024 – Medication and behavioral therapy are both effective in combatting fatigue caused by multiple sclerosis (MS), either separately or together, a new study finds. MS patients...
Cancer Incidence Increased for People With Multiple Sclerosis
WEDNESDAY, Oct. 9, 2024 – Cancer incidence is increased overall in people with multiple sclerosis (PwMS), with considerable differences depending on cancer type, age, and sex, according to a study...
Aggressive, Early Disease-Modifying Therapy May Slow MS Progression
FRIDAY, Sept. 27, 2024 – Reducing or preventing paramagnetic rim lesions (PRLs) could significantly slow multiple sclerosis (MS) progression, according to a study presented at the annual meeting of...
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...
Initial Symptoms of MS Could Guide Prognosis, Treatment
WEDNESDAY, Sept. 25, 2024 – Two key symptoms that can arise soon after a diagnosis of multiple sclerosis (MS) could predict how swiftly the illness will progress and suggest best treatment options,...
Higher Burden of Comorbidity Linked to Worse Clinical Outcomes in MS
MONDAY, Sept. 23, 2024 – For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according to a study published online Sept. 18 in JAMA...
Some People With MS May Need Earlier, Higher-Dose Meds
WEDNESDAY, Sept. 18, 2024 – Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a new study finds. Such treatment could prevent ...
Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children
CAMBRIDGE, Mass.--(BUSINESS WIRE) July 09, 2020 --Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration...
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
DUBLIN, Oct. 24, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application...